# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Michael Cherny maintains Hims & Hers Health (NYSE:HIMS) with a Buy and lowers the price target...
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The compan...
- SEC Filing
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing ...
- Reuters
Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has r...